ACTR-26. TOXICITY AND EFFICACY OF LOMUSTINE PLUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS

BACKGROUND: Bevacizumab combined with chemotherapy has shown high response rates in recurrent glioblastoma patients and responding patients have improved survival and quality of life. The Danish treatment recommendations for recurrent glioblastoma patients were recently changed by replacing irinotec...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Jakobsen, Jan Nyrop, Urup, Thomas, Grunnet, Kirsten, Christensen, Ib Jarle, Villingshøj, Mette, Poulsen, Hans Skovgaard
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692348/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.021
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi